Diazepam Buccal Film

A meaningful contribution to improved patient care

Diazepam buccal film is being developed as an oral rescue therapy for patients with breakthrough seizures or seizure clusters.

In the United States, 1.2 million people suffer from uncontrolled breakthrough seizures. Two hundred thousand additional people receive similar diagnoses each year.¹ The current standard of care for breakthrough seizures (or increased bouts of seizure activity) is rectally administered diazepam. However, this treatment’s lengthy, 14-step administration procedure may pose a barrier to use for many patients.²

Advancing treatment options for epilepsy

Administering diazepam on a buccal film could be less invasive and may provide the advantage of consistent, reliable absorption.^3-4

Our formulation team used PharmFilm® technology to develop a diazepam formulation that is absorbed directly through the buccal mucosa. The buccal mucosa’s wide, relatively immobile, and highly permeable surface area provided the stable and controlled microenvironment needed to optimize adhesion, absorption, and onset of action.

Our Quest: Deliver meaningful improvements

Our Chief Operating Officer, Dan Barber, discusses the hope to provide both patients and
providers with a new treatment option for breakthrough seizures.

“We think that giving patients the ability to take a product that doesn’t require any invasion is a
huge step forward.”

For more information on diazepam buccal film, download our case study “Overcoming Solubility and Permeability Challenges.”

Download now

Libervant (diazepam buccal film) is an investigational drug being evaluated for use in children and adults with refractory seizures, who remain on stable regimens of antiepileptic drugs, to control bouts of increased seizure activity. The product profile, data from our trials and related statements have not been approved by the FDA.

References

1. Chen B, Choi H, Hirsch LJ, et al. Prevalence and risk factors of breakthrough seizures in adult patients with epilepsy Epilepsy Res. 2017 Jul;133:98-102.

2. Diastat® diazepam rectal gel administration and disposal instructions. Bridgewater, NJ: Valeant Pharmaceuticals North America. 2017. http://www.diastat.com/Portals/_default/Skins/diastat/pdfs/Diastat%20Administration%20Instructions%204_2019.pdf.

3. Holsti M, Dudley N, Schunk J, et al. Intranasal midazolam vs rectal diazepam for the home treatment of acute seizures in pediatric patients with epilepsy. Arch Pediatr Adolesc Med. 2010;164(8):747–753.

4. Data on file. Warren Township, NJ: Aquestive Therapeutics.

Please complete this form:

Full name*
Email address*
Phone number*
What is your question?*
To subscribe to receive information updates about products and services from Aquestive Therapeutics, or to receive information about Aquestive-sponsored clinical trials, please check the box below. Please also review our privacy policy, which describes how we use and process your data. You may also contact us at any time by emailing info@aquestive.com or by calling 1-908-561-1900.
Subscribe
- I would like to receive information updates regarding products and services from Aquestive, and information about Aquestive-sponsored clinical trials.

Please complete the form below and click SEND to receive a copy of “Overcoming Solubility and Permeability Challenges,” a case study detailing the achievements made by Aquestive’s formulation team to create the diazepam buccal film.

Please complete the form to receive a demonstration kit for our PharmFilm® technology.

Full name*
Email address*
Street Address*
City*
Zip Code*
Phone number*
Tell us how we can help your brand
Send me a kit
- Send me a PharmFilm® demonstration kit
I am interested in:
- Commercializing an existing product
- Commercializing a product in development
- Investment opportunities
To subscribe to receive marketing updates about our PharmFilm® technology and other products and services from Aquestive, please complete the form below. Please also review our privacy policy, which describes how we use and process your data. You may also contact us at any time by emailing busdev@aquestive.com.
Subscribe
- I would like to receive marketing updates regarding products and services from Aquestive Therapeutics.

Please complete this form:

Full name*
Email address*
Phone number*
What is your question?*
In what clinical trial are you interested?
To subscribe to receive marketing updates about products and services from Aquestive Therapeutics, or to receive information about Aquestive-sponsored clinical trials, please check the box below. Please also review our privacy policy, which describes how we use and process your data. If for any reason you no longer wish to receive information on Aquestive-sponsored clinical trials, you can contact us at any time by emailing clinicaltrials@aquestive.com.
Subscribe
- I would like to receive information updates regarding products and services from Aquestive, and information about Aquestive-sponsored clinical trials.

Whether we are partnering to out license our PharmFilm® technology or in-licensing adjacent assets, Aquestive works hand-in-hand with our partners to address their toughest clinical and business challenges. To learn more, please complete the following form:

Full name*
Email address*
Phone number*
What is your question?*
To subscribe to receive information updates about products and services from Aquestive Therapeutics, or to receive information about Aquestive-sponsored clinical trials, please check the box below. Please also review our privacy policy, which describes how we use and process your data. You may also contact us at any time by emailing busdev@aquestive.com.
Subscribe
- I would like to receive information updates regarding products and services from Aquestive, and information about Aquestive-sponsored clinical trials.

Please complete the form below and click submit to receive a copy of “The Art of LGS Book.”

First Name*
Last Name*
Email Address*
Phone Number*
Role within the Epilepsy Community*
- Patient/Caregiver
- HCP
- Other
Tell us how we can assist you
- By providing my contact information, I agree that Aquestive Therapeutics (“Aquestive”) can use such information for its marketing database and that Aquestive and its agents may contact me by mail or email to provide information about Aquestive or its products or services. I understand that my contact information will not be sold to third parties, other than in the event Aquestive or its affiliates are sold. I understand that I have the right to opt-out of the database and have my information removed from the database at any time. Instructions on how to be removed from the database will be included in any future communications sent to me by Aquestive. Please also review our privacy policy, which describes how we use and process your data. You may also contact us at any time by emailing lgsart@aquestive.com.

Diazepam Buccal Film

A meaningful contribution to improved patient care

Advancing treatment options for epilepsy

Our Quest: Deliver meaningful improvements

Advantages of Diazepam Buccal Film Formulation

“We think that giving patients the ability to take a product that doesn’t require any invasion is a huge step forward.”

For more information on diazepam buccal film, download our case study “Overcoming Solubility and Permeability Challenges.”

References

Please complete this form:

Please complete the form below and click SEND to receive a copy of “Overcoming Solubility and Permeability Challenges,” a case study detailing the achievements made by Aquestive’s formulation team to create the diazepam buccal film.

Please complete the form to receive a demonstration kit for our PharmFilm® technology.

Please complete this form:

Whether we are partnering to out license our PharmFilm® technology or in-licensing adjacent assets, Aquestive works hand-in-hand with our partners to address their toughest clinical and business challenges. To learn more, please complete the following form:

Please complete the form below and click submit to receive a copy of “The Art of LGS Book.”

Advantages of Diazepam Buccal
Film Formulation

“We think that giving patients the ability to take a product that doesn’t require any invasion is a
huge step forward.”